Paclitaxel

Catalog No.S1150 Synonyms: NSC 125973

Paclitaxel Chemical Structure

Molecular Weight(MW): 853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • (F) Kaplan-Meier curves are shown for all groups described: no hydrogel, a hydrogel loaded with paclitaxel, or a hydrogel loaded with doxorubicin. The number of mice per group (n) and median survival (ms) are listed. The experiment was performed at least three times.

    Science, 2018, 10(433), doi: 10.1126/scitranslmed.aar1916. Paclitaxel purchased from Selleck.

    Characterization of nuclear damage by PARP as DNA damage repair marker. CLSM images of dual drug conjugated nanoparticle treatments to HeLa cells for 24 h at their respective IC50 drug dosages compared to nontreated control. Cells were stained with PARP-Alexafluor 488 antibody (green).

    ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck.

  • Microscope image (406) magnification of U937 cells after exposure to SM-TNs. a) Untreated U937 cells. b) U937 cells treated with 200 nM, and 35 nM ODS empty shells. c) U937 cells treated with microcrystalline (free) Taxol prepared by sonicating Taxol in 20%H3PO4/0.8% SDS solution. d) U937 cells treated with 200 nM SM-TN. A SM-TN is seen in the middle of the picture. e) U937 cells treated with 35 nM SMTN.The nanowires are too small to see at this magnification, but their effect on the cells is clearly visible. Scale bar = 10 mm.

    RSC Adv 2011 1, 884-892. Paclitaxel purchased from Selleck.

    Inhibitory effect of lenvatinib and paclitaxel on the proliferation of ATC cells. Cells were treated with the indicated concentrations of lenvatinib (A) and paclitaxel (B) for 48 h, followed by MTT assay to evaluate cell proliferation. IC50 values of these two drugs for each cell line were calculated using the Reed-Muench method

    Am J Cancer Res, 2017, 7(4):903-912. Paclitaxel purchased from Selleck.

  • Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 0.37 μM or 10 μM paclitaxel in three-dimensional cell culture for 24 hours.

    PLoS One, 2016, 11(5):e0155052. . Paclitaxel purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
Targets
Microtubule (human endothelial cells) [1]
0.1 pM
In vitro

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 MkXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;1b3RKSzVyPUCuNFAxOjh5IN88US=> MWnTRW5ITVJ?
LC-2-ad MnK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPXTWM2OD1yLkCwNFMyPyEQvF2= M2HjWXNCVkeHUh?=
RL95-2 MlT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzpTWM2OD1yLkCwNFY3QCEQvF2= NEDRPZpUSU6JRWK=
MZ1-PC NX;yW4NvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHXPXJKSzVyPUCuNFAxPzJ7IN88US=> M{OwdXNCVkeHUh?=
TE-8 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\PTWM2OD1yLkCwNVE4KM7:TR?= M3\O[XNCVkeHUh?=
SW954 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fhfmlEPTB;MD6wNFEyQSEQvF2= MlPrV2FPT0WU
TE-11 MmCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwMECxNlMh|ryP NYPYc3pGW0GQR1XS
PSN1 NFHyRVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2SzXmlEPTB;MD6wNFE{KM7:TR?= Mo\SV2FPT0WU
MOLT-4 M{TBUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\O[|NKSzVyPUCuNFAyPDlizszN M4jGfHNCVkeHUh?=
697 NU\DPJFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPsWYNJUUN3ME2wMlAxOTVizszN MUjTRW5ITVJ?
ETK-1 M{fJW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\DV4RKSzVyPUCuNFAyPTJizszN NIfoOmJUSU6JRWK=
TE-10 M2q0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37ufmlEPTB;MD6wNFE2PCEQvF2= NYP5SHR{W0GQR1XS
HUTU-80 NXvBNW57T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjCTWM2OD1yLkCwNVY5KM7:TR?= MV;TRW5ITVJ?
NTERA-S-cl-D1 Mnm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHTTWM2OD1yLkCwNlA6KM7:TR?= MYfTRW5ITVJ?
MFH-ino MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;hSGlEPTB;MD6wNFI3QCEQvF2= Mn;UV2FPT0WU
IA-LM NVvST21kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4riWmlEPTB;MD6wNFI5KM7:TR?= M1\VUXNCVkeHUh?=
MC116 MnnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PxdGlEPTB;MD6wNFI5QSEQvF2= Mli3V2FPT0WU
RKO NVzIe|d[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLaflJKSzVyPUCuNFAzQThizszN NWHleIZEW0GQR1XS
MRK-nu-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzxVHVYUUN3ME2wMlAxOjl7IN88US=> MlfaV2FPT0WU
VA-ES-BJ NFnKcFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NID1bnNKSzVyPUCuNFA{KM7:TR?= Mk\FV2FPT0WU
KALS-1 NI\MT5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVGyXnppUUN3ME2wMlAxOzB6IN88US=> NYPtZnp5W0GQR1XS
BB30-HNC Moi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\HPIlKSzVyPUCuNFA{OTRizszN M1LWWnNCVkeHUh?=
ACN M{jNbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVWxVm9sUUN3ME2wMlAxOzF4IN88US=> NIfEdo9USU6JRWK=
TE-9 NGLpN4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPkXpNoUUN3ME2wMlAxOzJ4IN88US=> NGfpUoFUSU6JRWK=
SIG-M5 NUPzO2pHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH6xeZVKSzVyPUCuNFA{OjdizszN M4HrWHNCVkeHUh?=
no-10 M3vsPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwMECzOlIh|ryP NUC0cGFEW0GQR1XS
EW-1 M2ns[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwMECzO|Eh|ryP NIrMWlRUSU6JRWK=
SK-LMS-1 NVPOc2hHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDGbHYyUUN3ME2wMlAxPDBzIN88US=> NYGxVmpZW0GQR1XS
GT3TKB M2X6eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXtUZhKSzVyPUCuNFA1OzRizszN MoDpV2FPT0WU
ES4 NVHFZ|RMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTBwMEC0OFkh|ryP MojvV2FPT0WU
IMR-5 MkH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXGTWM2OD1yLkCwOFUh|ryP MoTkV2FPT0WU
NCI-H1648 NFm1[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{f4ZWlEPTB;MD6wNFQ3QSEQvF2= NYPmdYtIW0GQR1XS
MV-4-11 NWeyZ2g5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvSUmpKSzVyPUCuNFA1PzVizszN NULHV|BuW0GQR1XS
SK-UT-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TPVWlEPTB;MD6wNFQ5KM7:TR?= M1jZfnNCVkeHUh?=
NB13 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGO3SVRKSzVyPUCuNFA1QTFizszN NYC2fYFbW0GQR1XS
DJM-1 NH7ZW4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3W3RmlEPTB;MD6wNFU{KM7:TR?= NXfvdJFbW0GQR1XS
ES8 Mo\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTTcY5PUUN3ME2wMlAxPTN6IN88US=> NFm4XWlUSU6JRWK=
TE-6 NVL5Wo9IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwMEC1O{DPxE1? MoXhV2FPT0WU
KS-1 Ml;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XlXGlEPTB;MD6wNFU5OiEQvF2= NVHWO3dqW0GQR1XS
TE-1 M4q5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwMEC2NFYh|ryP NWf0dVh2W0GQR1XS
ATN-1 NUDmZVdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWO5fY5wUUN3ME2wMlAxPjB7IN88US=> Ml[5V2FPT0WU
A4-Fuk NY\lS2ZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnSTWM2OD1yLkCwOlEyKM7:TR?= M2jYdnNCVkeHUh?=
ALL-PO MnzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPXenhKSzVyPUCuNFA3OyEQvF2= M2PtVXNCVkeHUh?=
BE-13 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGG1e25KSzVyPUCuNFA3OzZizszN MoLIV2FPT0WU
KM12 M2GxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYX5N2d7UUN3ME2wMlAxPjN5IN88US=> MlLKV2FPT0WU
NOS-1 M2Sybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwMEC2OUDPxE1? NVTPdHp2W0GQR1XS
SW962 MkXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTBwMEC2OlIh|ryP NYL5eVBsW0GQR1XS
OCUB-M NFnBVFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7wTlNKSzVyPUCuNFA3PjJizszN NFX3dlZUSU6JRWK=
NCI-H510A M2\JdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWX2[WFjUUN3ME2wMlAxPjZ3IN88US=> NIrtSHVUSU6JRWK=
EW-16 MkTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjWXZZpUUN3ME2wMlAxPjl2IN88US=> MVvTRW5ITVJ?
KGN NWP2R4h5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwMEC3NVIh|ryP M33tXXNCVkeHUh?=
LS-411N MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jaPGlEPTB;MD6wNFcyPyEQvF2= M1m2N3NCVkeHUh?=
Becker M4nMWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwMEC3NkDPxE1? M4\KTXNCVkeHUh?=
HC-1 MoC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGD0NZJKSzVyPUCuNFA4OjFizszN NYrNc4l[W0GQR1XS
CESS MmHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHy1eJRKSzVyPUCuNFA4OzdizszN M1rkV3NCVkeHUh?=
KURAMOCHI NWPnUGs4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfnS|NKSzVyPUCuNFA4PDhizszN NUjJflFJW0GQR1XS
TGBC24TKB M3mzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DSXmlEPTB;MD6wNFc2OiEQvF2= NILmOXZUSU6JRWK=
SW982 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwMEC3OlYh|ryP MmG2V2FPT0WU
HCE-4 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVK1[mFtUUN3ME2wMlAxPzZ5IN88US=> MmHqV2FPT0WU
LOUCY MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLuTWM2OD1yLkCwO|c2KM7:TR?= NHfRR3BUSU6JRWK=
8-MG-BA Mnq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFS2ZVdKSzVyPUCuNFA4QTZizszN M{\LfnNCVkeHUh?=
HT-144 M{fnW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTITWM2OD1yLkCwPEDPxE1? NWW4c4N1W0GQR1XS
LXF-289 NHnBU4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfWeFRKSzVyPUCuNFA5OThizszN NYm3eFNuW0GQR1XS
RS4-11 M17pbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\vNGZCUUN3ME2wMlAxQDN4IN88US=> NIPsR5RUSU6JRWK=
DEL NGLZSINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwMEC4OFUh|ryP M{P6fHNCVkeHUh?=
OCI-AML2 M{\ZeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUL2ZXdMUUN3ME2wMlAxQDV{IN88US=> NIfQSY5USU6JRWK=
CCRF-CEM NX:wS3J1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3NVpZEUUN3ME2wMlAxQDdzIN88US=> MlXWV2FPT0WU
A388 NX\YeFIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{n2cmlEPTB;MD6wNFg4PCEQvF2= NX2ybmV[W0GQR1XS
KNS-42 NF3QbYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvQTWM2OD1yLkCwPFkyKM7:TR?= M4T4V3NCVkeHUh?=
OVCAR-4 NHy3RWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDDcYhbUUN3ME2wMlAxQTB2IN88US=> MVHTRW5ITVJ?
NCI-H1355 M33IPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwMEC5NVQh|ryP NUm2TXVZW0GQR1XS
BL-70 NYOydot2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorXTWM2OD1yLkCwPVMh|ryP NHTMU2VUSU6JRWK=
BL-41 M{HsOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwMEC5N|Qh|ryP MnzLV2FPT0WU
A101D NWC4dpV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojETWM2OD1yLkCwPVYh|ryP NHfPN|RUSU6JRWK=
HL-60 M4XqXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwMEC5OlYh|ryP NIfDO25USU6JRWK=
COR-L279 NV:yW2Q5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULjRY1IUUN3ME2wMlAxQTl7IN88US=> M{jEcnNCVkeHUh?=
NCI-SNU-16 M1TxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PUcGlEPTB;MD6wNVAxQCEQvF2= M2HkUHNCVkeHUh?=
Calu-6 NIjvVodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVziXWR4UUN3ME2wMlAyODF{IN88US=> NYftNWxKW0GQR1XS
SR NYHxWFZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPBN3dKSzVyPUCuNFExOjZizszN M2\xV3NCVkeHUh?=
QIMR-WIL M{OwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PxNmlEPTB;MD6wNVA{OyEQvF2= MljtV2FPT0WU
LB647-SCLC MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULiZZJnUUN3ME2wMlAyODVzIN88US=> MYLTRW5ITVJ?
RPMI-8226 NUXBeWJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTKOWFJUUN3ME2wMlAyOTB{IN88US=> NEjPboNUSU6JRWK=
SK-PN-DW NIfk[GZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnEWmltUUN3ME2wMlAyOTF{IN88US=> NGrUZm5USU6JRWK=
SF268 M2jWcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPJSWIxUUN3ME2wMlAyOTVzIN88US=> Mln5V2FPT0WU
HD-MY-Z NVzpU3JPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTBwMEGxOlMh|ryP MXPTRW5ITVJ?
DOHH-2 NV7HTZpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXQc4U2UUN3ME2wMlAyOjB|IN88US=> M4j2b3NCVkeHUh?=
SCC-3 Mn3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\ITWM2OD1yLkCxNlA1KM7:TR?= M2DUNHNCVkeHUh?=
ST486 M3\3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4T5cWlEPTB;MD6wNVIxPCEQvF2= MmPOV2FPT0WU
NALM-6 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlP2TWM2OD1yLkCxNlE1KM7:TR?= NWfwNGw4W0GQR1XS
NCI-H1436 NGPD[FhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfsNVY{UUN3ME2wMlAyOjNzIN88US=> NW\mSII6W0GQR1XS
KE-37 M2HXNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjPW2pnUUN3ME2wMlAyOjN2IN88US=> MmW2V2FPT0WU
RPMI-8402 NHThUYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XQfmlEPTB;MD6wNVI2PiEQvF2= NVfWenoxW0GQR1XS
RXF393 M33COmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwMEGyOVch|ryP MVPTRW5ITVJ?
KARPAS-45 NX;0OoNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHafVJJUUN3ME2wMlAyOjdizszN NGHGSppUSU6JRWK=
HOP-62 NFLae4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;zTWM2OD1yLkCxNlc3KM7:TR?= MYLTRW5ITVJ?
ES1 MkD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTiR|FKSzVyPUCuNFEzQDhizszN MnfaV2FPT0WU
L-363 NIP4XJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWq2fmJpUUN3ME2wMlAyOzVzIN88US=> NVHEO|RsW0GQR1XS
GI-1 MoTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLxOYhtUUN3ME2wMlAyOzd|IN88US=> NYD6[XNVW0GQR1XS
CTV-1 MoO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2f2fWlEPTB;MD6wNVQ4QCEQvF2= M3XlSXNCVkeHUh?=
TE-5 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPXTWM2OD1yLkCxOFk3KM7:TR?= MVrTRW5ITVJ?
SNU-C2B NWLkbG5sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwMEG0PVYh|ryP MWDTRW5ITVJ?
K-562 MnnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHxc2lKSzVyPUCuNFE2OTZizszN NGfme49USU6JRWK=
SNB75 Mlf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{myUWlEPTB;MD6wNVU1KM7:TR?= M1PhT3NCVkeHUh?=
MOLT-13 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWe4T5hsUUN3ME2wMlAyPjN5IN88US=> MX3TRW5ITVJ?
LS-123 MonXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Kxd2lEPTB;MD6wNVY3PCEQvF2= NGLlSHRUSU6JRWK=
NCI-SNU-5 NILoTGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnKTWM2OD1yLkCxO|AyKM7:TR?= MVnTRW5ITVJ?
Daudi NYj2WJhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7DTY45UUN3ME2wMlAyPzB6IN88US=> NIHXUZdUSU6JRWK=
A253 M{PVWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlL3TWM2OD1yLkCxO|M5KM7:TR?= NX\0[WdRW0GQR1XS
TGBC1TKB MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHQ[5FmUUN3ME2wMlAyPzV{IN88US=> MlfkV2FPT0WU
SJSA-1 MojOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTBwMEG3Olch|ryP MmDaV2FPT0WU
NCCIT MnX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\YfVhKSzVyPUCuNFE4PjlizszN NY\kWVlyW0GQR1XS
NCI-H69 M{fEdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnpeW1KSzVyPUCuNFE4PzhizszN M{nKU3NCVkeHUh?=
SH-4 MlmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTBwMEG4PVUh|ryP Ml7uV2FPT0WU
HCC1187 M13KXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwMEG5NlQh|ryP MUDTRW5ITVJ?
HCC1599 M4Cwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTBwMEKwNkDPxE1? MkfrV2FPT0WU
ONS-76 MmPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDDUJJKSzVyPUCuNFIxOzZizszN MnzUV2FPT0WU
KU812 M165WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTBwMEKwN|kh|ryP MUfTRW5ITVJ?
ML-2 NGi4bXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWP5WIZCUUN3ME2wMlAzODR5IN88US=> M17ydnNCVkeHUh?=
HCE-T M{jFXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzsTWM2OD1yLkCyNFkzKM7:TR?= M12zUnNCVkeHUh?=
NCI-H446 NXu2N3pST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33kVGlEPTB;MD6wNlEyOiEQvF2= NUC2PZMzW0GQR1XS
RPMI-6666 M1XiT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TyO2lEPTB;MD6wNlE1QSEQvF2= NIPES|dUSU6JRWK=
MOLT-16 M4i1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmD6TWM2OD1yLkCyNVU{KM7:TR?= MoPYV2FPT0WU
JiyoyeP-2003 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LN[GlEPTB;MD6wNlE4PiEQvF2= NGT6OYJUSU6JRWK=
MHH-PREB-1 NHrnOVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwMEKxPVEh|ryP NEfNbWxUSU6JRWK=
MC-CAR NWDyWHZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;RdppLUUN3ME2wMlAzOzJ4IN88US=> NFLCXWZUSU6JRWK=
BC-3 M1GyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\WeopKSzVyPUCuNFI{PDRizszN MoftV2FPT0WU
KINGS-1 M1myZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwMEKzOVUh|ryP NVrwZ4VjW0GQR1XS
PF-382 NGjENnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPwTWM2OD1yLkCyN|c5KM7:TR?= NWruWWR3W0GQR1XS
J-RT3-T3-5 M1fSbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLrR|JKSzVyPUCuNFI{QDNizszN MYXTRW5ITVJ?
SF539 MmPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTBwMEK0NFEh|ryP MoDlV2FPT0WU
LB831-BLC NIjQO21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3i2c2lEPTB;MD6wNlQ5PSEQvF2= M3fsWnNCVkeHUh?=
DMS-114 NYPG[HBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPzdG5KSzVyPUCuNFI2ODJizszN NWPzepVwW0GQR1XS
LB1047-RCC NYrBV4VmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwMEK1NUDPxE1? MWrTRW5ITVJ?
LB771-HNC NVTE[FRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTBwMEK1N|Qh|ryP NULzXIFGW0GQR1XS
BB65-RCC NVr5WpBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFO0WHVKSzVyPUCuNFI2OzRizszN MorHV2FPT0WU
BV-173 NEK4U4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLLWpdXUUN3ME2wMlAzPTV2IN88US=> MoLCV2FPT0WU
ARH-77 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkL6TWM2OD1yLkCyOlAyKM7:TR?= M37TXXNCVkeHUh?=
IST-MEL1 NIq2d2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vpW2lEPTB;MD6wNlYzOyEQvF2= NFnCcXVUSU6JRWK=
NB1 M2e1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIT0eVJKSzVyPUCuNFI3QDdizszN NXO4b2I5W0GQR1XS
EoL-1-cell MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnOdJZKSzVyPUCuNFI3QDhizszN MmDRV2FPT0WU
KY821 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXkRlVCUUN3ME2wMlAzPjl5IN88US=> MmO2V2FPT0WU
CMK M1T2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\Dc4I6UUN3ME2wMlAzPzN2IN88US=> MWLTRW5ITVJ?
NCI-H2126 NFm0cnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTBwMEK3Olgh|ryP Mmn2V2FPT0WU
NCI-H526 NHXDXnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHGTGxSUUN3ME2wMlAzQDlzIN88US=> MoXYV2FPT0WU
COLO-684 M3\ZU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwMEK5NFgh|ryP NVrae4VYW0GQR1XS
NCI-H747 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXpelVKSzVyPUCuNFI6OzNizszN NFrLTFBUSU6JRWK=
JAR M2e1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjUe4hKSzVyPUCuNFI6PDZizszN MY\TRW5ITVJ?
MEG-01 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTBwMEK5O|gh|ryP M4L0b3NCVkeHUh?=
MONO-MAC-6 M3fp[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXr6WFNLUUN3ME2wMlA{ODJ|IN88US=> M{S3R3NCVkeHUh?=
IST-SL1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTBwMEOwOFIh|ryP MUXTRW5ITVJ?
CPC-N Mnm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fwTWlEPTB;MD6wN|A4QSEQvF2= M3z2WnNCVkeHUh?=
NCI-H1963 M3fxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwMEOxN|Eh|ryP NXLOfoZbW0GQR1XS
K052 MlfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFr0fFVKSzVyPUCuNFMzPDdizszN Mmq1V2FPT0WU
KM-H2 M{\ybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfMPGlKSzVyPUCuNFM{ODdizszN Ml;WV2FPT0WU
TE-12 MkTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\tTWM2OD1yLkCzN|A6KM7:TR?= NV7w[XEzW0GQR1XS
TK10 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fnPGlEPTB;MD6wN|M2PiEQvF2= M4DIdXNCVkeHUh?=
NMC-G1 M2n6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3DRplTUUN3ME2wMlA{PDV{IN88US=> NFvwNHRUSU6JRWK=
no-11 M1u3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHGxSIZKSzVyPUCuNFM1PzhizszN M1;XXHNCVkeHUh?=
NCI-H524 MmDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwMEO1Nlkh|ryP NX76c4VPW0GQR1XS
MHH-CALL-2 M2fSW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2POdWlEPTB;MD6wN|U3OiEQvF2= MV\TRW5ITVJ?
GB-1 MoToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTqTWM2OD1yLkCzOkDPxE1? NGK4V29USU6JRWK=
OPM-2 NGHIWWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrWTlI4UUN3ME2wMlA{Pjd|IN88US=> Mm\HV2FPT0WU
RH-1 NV[2dINbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTBTWM2OD1yLkCzPFE6KM7:TR?= M13ZUXNCVkeHUh?=
NCI-H64 NFzsO|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfTUGFKSzVyPUCuNFM5PTdizszN NUHZVmFYW0GQR1XS
EVSA-T MnHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\lWVhKSzVyPUCuNFM6OjNizszN M3qzdHNCVkeHUh?=
KARPAS-299 NXfvW2JiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2C1S2lEPTB;MD6wN|k5KM7:TR?= MXzTRW5ITVJ?
MZ7-mel NX7JXWlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwMESwOEDPxE1? MUnTRW5ITVJ?
LB373-MEL-D NFHkS2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFH0SpBKSzVyPUCuNFQyODVizszN NFq2ZmNUSU6JRWK=
HEL NV;UTYVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPON5g3UUN3ME2wMlA1OTRizszN MkPnV2FPT0WU
SW872 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[xcolKSzVyPUCuNFQzOSEQvF2= NFjrclJUSU6JRWK=
DU-4475 NU\OcG1bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHabFdKSzVyPUCuNFQzPDRizszN MUfTRW5ITVJ?
IST-SL2 NGDY[mZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnCXJlKSzVyPUCuNFQzPzVizszN MVTTRW5ITVJ?
NCI-H82 NGHJcI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrMWYtIUUN3ME2wMlA1OzB5IN88US=> MX;TRW5ITVJ?
LC4-1 MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTtdmhKSzVyPUCuNFQ{PTFizszN MnL5V2FPT0WU
HDLM-2 NWryeXhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwMESzPVIh|ryP NIXXXXVUSU6JRWK=
MMAC-SF M3W5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHGTWM2OD1yLkC0OVM1KM7:TR?= NE[xSGFUSU6JRWK=
L-540 MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXTWIhtUUN3ME2wMlA1PjN7IN88US=> NIrKc5VUSU6JRWK=
MZ2-MEL M3iyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3YTWM2OD1yLkC0O|QzKM7:TR?= MoDUV2FPT0WU
LU-134-A M4Tubmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwMES3O|Mh|ryP NYPoSnZWW0GQR1XS
UACC-257 NXr4OYZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HofGlEPTB;MD6wOFg1QSEQvF2= M1m4SnNCVkeHUh?=
NCI-H1581 MmjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvQVI1KSzVyPUCuNFQ6PTNizszN M2e1OXNCVkeHUh?=
NB17 M3X5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwMES5O|kh|ryP NIDpSodUSU6JRWK=
SBC-1 MlfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwMEWwOFIh|ryP NFHpfoJUSU6JRWK=
TALL-1 M4qwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnOTWM2OD1yLkC1NFQ2KM7:TR?= NXzjTlhEW0GQR1XS
NCI-H1304 NEKwVZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojXTWM2OD1yLkC1NlA5KM7:TR?= NFT1ToJUSU6JRWK=
NEC8 NFS4OFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfIXlZpUUN3ME2wMlA2Ojh4IN88US=> MUDTRW5ITVJ?
CAL-148 NVn2cXpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;uTWM2OD1yLkC1OFM6KM7:TR?= M4XsbHNCVkeHUh?=
CGTH-W-1 NH3Tb4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfWb3lLUUN3ME2wMlA2PDR7IN88US=> MYfTRW5ITVJ?
NCI-H889 M{P1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3NdnpKSzVyPUCuNFU2QTJizszN MUnTRW5ITVJ?
GR-ST M1zKbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TpUmlEPTB;MD6wOVYzOSEQvF2= M3jKc3NCVkeHUh?=
KARPAS-422 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4ru[mlEPTB;MD6wOVY2KM7:TR?= NIW3PIZUSU6JRWK=
RPMI-8866 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTBwMEW3NVIh|ryP M{PHTHNCVkeHUh?=
SCLC-21H Mm\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrZdFZKSzVyPUCuNFU5QDRizszN MUnTRW5ITVJ?
COR-L88 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\3UmlEPTB;MD6wOVkzPyEQvF2= NIe5VoZUSU6JRWK=
LU-139 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGewdoJKSzVyPUCuNFU6QDZizszN NH2zeYpUSU6JRWK=
SF126 NF7nUGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13QfWlEPTB;MD6wOlE{OyEQvF2= MnzpV2FPT0WU
NCI-H1882 NVXaSFlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVT1bYRQUUN3ME2wMlA3PDJ2IN88US=> MUHTRW5ITVJ?
EW-24 NWDBOZIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXru[|R6UUN3ME2wMlA3PDh|IN88US=> NFvUXplUSU6JRWK=
CP67-MEL NWPLc4pQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPPZop{UUN3ME2wMlA3QDFizszN MX;TRW5ITVJ?
DG-75 M163dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfzZ2p1UUN3ME2wMlA3QDl7IN88US=> MWTTRW5ITVJ?
LOXIMVI MnrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3CfWpiUUN3ME2wMlA4ODJ6IN88US=> MX7TRW5ITVJ?
HH NEm5eIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrMR5BKSzVyPUCuNFcyPTdizszN M{\MSnNCVkeHUh?=
K5 NXLK[4p7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHyZ|A6UUN3ME2wMlA4OjJ4IN88US=> NWLUTpIyW0GQR1XS
EC-GI-10 NEe0SINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHSzc29KSzVyPUCuNFczPTdizszN Mo\RV2FPT0WU
SK-N-DZ NVvtWHg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHYbo1yUUN3ME2wMlA4OzB5IN88US=> M33TWXNCVkeHUh?=
A3-KAW NYr0dWFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XHfGlEPTB;MD6wO|M2OSEQvF2= MlzFV2FPT0WU
MLMA NYnWTVN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;SO|dsUUN3ME2wMlA4PDZ3IN88US=> MkXSV2FPT0WU
LB996-RCC M3i2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3ryfGlEPTB;MD6wO|cxPyEQvF2= NEjWeJBUSU6JRWK=
OS-RC-2 M16zZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTBwMEe3OFgh|ryP NIPaVXJUSU6JRWK=
CTB-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjuNXVKSzVyPUCuNFc5OSEQvF2= NITUcHdUSU6JRWK=
IST-MES1 M3OxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fwTGlEPTB;MD6wO|kyOiEQvF2= MYHTRW5ITVJ?
LS-1034 NFvxTZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknxTWM2OD1yLkC4NFM2KM7:TR?= NIm5bFVUSU6JRWK=
HT MlnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjZdoZLUUN3ME2wMlA5ODh4IN88US=> NEDoNJpUSU6JRWK=
NCI-H2141 MoT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwMEixJO69VQ>? MUDTRW5ITVJ?
LB2518-MEL MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGizOXdKSzVyPUCuNFgyPDFizszN MlnEV2FPT0WU
GI-ME-N NU\UVppvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPmVnNKSzVyPUCuNFg1PTJizszN NWSySnp5W0GQR1XS
TGW MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnL[odKSzVyPUCuNFg3ODdizszN NXvkUYp4W0GQR1XS
SK-NEP-1 MonXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULlU45PUUN3ME2wMlA5PjRzIN88US=> NGLS[ZRUSU6JRWK=
NOMO-1 M3W2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MluyTWM2OD1yLkC5Nlc2KM7:TR?= M3jye3NCVkeHUh?=
ES6 NWH0XYFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHXbFRKSzVyPUCuNFk2QDlizszN MUDTRW5ITVJ?
NCI-H209 M3O2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TZ[WlEPTB;MD6wPVc5PiEQvF2= MYXTRW5ITVJ?
GAK NFvpPZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLtTWM2OD1yLkGwNVYh|ryP MW\TRW5ITVJ?
BC-1 NY\6N2o{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwMUCzOlEh|ryP M123[HNCVkeHUh?=
KLE NVTkRmNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{m2RWlEPTB;MD6xNFQ1OyEQvF2= NF7Qd4lUSU6JRWK=
EW-3 NGrHRmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;ZTWM2OD1yLkGwPVgh|ryP MWrTRW5ITVJ?
NKM-1 M1HuOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\vbllZUUN3ME2wMlEyOSEQvF2= NVvoVGtFW0GQR1XS
D-336MG MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPJTWM2OD1yLkGxNlQ1KM7:TR?= M2HZPXNCVkeHUh?=
NB69 NHrhXG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHf0RlZKSzVyPUCuNVE{ODFizszN M3nzSXNCVkeHUh?=
D-263MG MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLGW4ZKSzVyPUCuNVE4OTJizszN NG\vb4VUSU6JRWK=
KP-N-YS NY[wfIJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rjcGlEPTB;MD6xNlI6OSEQvF2= Ml\MV2FPT0WU
NCI-H1155 M3fuXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorxTWM2OD1yLkGyOVU5KM7:TR?= NWPyXIpWW0GQR1XS
BOKU M2X5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWT3NZdVUUN3ME2wMlEzPTd7IN88US=> NEHFSWJUSU6JRWK=
LAMA-84 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTBwMUK5PUDPxE1? NE[zVFZUSU6JRWK=
Raji MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVP0XWlDUUN3ME2wMlE{OTF5IN88US=> MoDpV2FPT0WU
LU-65 NEP4XlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPaVpFKSzVyPUCuNVM{ODdizszN NVXzUGR2W0GQR1XS
NCI-H187 M3P3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXhbJJKSzVyPUCuNVM6OjRizszN M{CwZnNCVkeHUh?=
GCIY MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;rbWlEPTB;MD6xOFkxOSEQvF2= M2fMTXNCVkeHUh?=
NCI-H2107 M1XhV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwMUWwPEDPxE1? M4H1[XNCVkeHUh?=
NCI-H1522 NEHwR5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTBwMUWyOlYh|ryP NFPDbm1USU6JRWK=
NB6 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfSZ49KSzVyPUCuNVU3OjNizszN M{XmWXNCVkeHUh?=
EM-2 NW[4WHZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{G2fGlEPTB;MD6xOVcxPiEQvF2= NHHhU5ZUSU6JRWK=
HCC2218 NFX0SINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nqV2lEPTB;MD6xOVk5KM7:TR?= NXG5bIhyW0GQR1XS
NCI-H748 NXq4b5BwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrrbJlKSzVyPUCuNVY{PzZizszN M1zqd3NCVkeHUh?=
MS-1 NVrRNGFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzNe2JtUUN3ME2wMlE3PTN5IN88US=> M4DaSXNCVkeHUh?=
NB5 MlvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwMU[1PVch|ryP M4rTVHNCVkeHUh?=
OMC-1 NVntUoUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTobmFwUUN3ME2wMlE3Pjh6IN88US=> NGjiWVZUSU6JRWK=
NCI-H345 NV3q[25yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPyTWM2OD1yLkG2PVI5KM7:TR?= MlLFV2FPT0WU
L-428 NFT3XWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jUNWlEPTB;MD6xOlk1PSEQvF2= NV\WXZJYW0GQR1XS
SCH NU\PUWlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlu5TWM2OD1yLkG4Olg2KM7:TR?= MWTTRW5ITVJ?
NCI-H1417 M{TsVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4L1O2lEPTB;MD6xPVIzPyEQvF2= MYTTRW5ITVJ?
COLO-320-HSR MnvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1z0fWlEPTB;MD6xPVU{OiEQvF2= NF\6WGxUSU6JRWK=
BT-474 NU\ORW9YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jYVWlEPTB;MD6yNFg6OiEQvF2= MknCV2FPT0WU
GDM-1 MnfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrqNXdlUUN3ME2wMlIyQTdzIN88US=> MX3TRW5ITVJ?
NCI-H2196 MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfTcFB[UUN3ME2wMlIzOjN3IN88US=> NFnIT2tUSU6JRWK=
KP-N-RT-BM-1 NIrKcpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTBR5pKSzVyPUCuNlI{PDlizszN NV\j[3R4W0GQR1XS
KNS-81-FD MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwMkK5OVgh|ryP Mo\ZV2FPT0WU
COLO-668 NITCS2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjOTWM2OD1yLkKzOlc2KM7:TR?= MU\TRW5ITVJ?
C2BBe1 M3[wXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEG5RWJKSzVyPUCuNlY4PDdizszN MWfTRW5ITVJ?
Ramos-2G6-4C10 NF\HXI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzm[|ZKSzVyPUCuNlY6PTRizszN M{H1ZnNCVkeHUh?=
CAS-1 MkPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwMkewPVYh|ryP M4rnV3NCVkeHUh?=
GOTO MmHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLKTWM2OD1yLkK3PFk1KM7:TR?= NI\MUWVUSU6JRWK=
LP-1 NUTuN|M5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUL3NY5lUUN3ME2wMlI5ODV5IN88US=> MXzTRW5ITVJ?
NCI-SNU-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGf2cXJKSzVyPUCuNlk1OjJizszN M2DlUHNCVkeHUh?=
EB-3 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3ezb2lEPTB;MD6yPVk4QSEQvF2= M1r5R3NCVkeHUh?=
MHH-NB-11 MlLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHFOFJKSzVyPUCuN|A1ODJizszN NGrGcJRUSU6JRWK=
SK-N-FI NVvHd3lwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\GTWM2OD1yLkOxOlkzKM7:TR?= M{m3SXNCVkeHUh?=
HCC2157 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPTTWM2OD1yLkOzPVE{KM7:TR?= NHjRVYJUSU6JRWK=
SIMA M33NO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlG4TWM2OD1yLkO0OVgyKM7:TR?= NV6zZ4ZXW0GQR1XS
MDA-MB-134-VI NXvKdHJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwM{[5Nlgh|ryP NHv5cYlUSU6JRWK=
NCI-H1694 MoTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\oT2V3UUN3ME2wMlM4KM7:TR?= NILleoJUSU6JRWK=
EHEB M3LqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwM{mwPFUh|ryP MonBV2FPT0WU
U-266 M1jRVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXyc|RKSzVyPUCuN|k5PDZizszN NHX6V3dUSU6JRWK=
LC-1F M{fVdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTBwNEO3OlUh|ryP NWT5O3dLW0GQR1XS
SHP-77 NVfIbItZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7tbINKSzVyPUCuOFc5PTVizszN Mki1V2FPT0WU
LS-513 M4fS[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPoXGFKSzVyPUCuOFk{ODdizszN MnP4V2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
  • Concentrations: 0.1-100 pM
  • Incubation Time: 72 hours
  • Method:

    Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
  • Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
  • Dosages: 20 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+5% Tween 80+ddH2O
For best results, use promptly after mixing.
2.5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 853.91
Formula

C47H51NO14

CAS No. 33069-62-4
Storage powder
in solvent
Synonyms NSC 125973

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02181634 Active, not recruiting Cholangiocarcinoma PrECOG, LLC.|Celgene Corporation December 9, 2014 Phase 2
NCT03047265 Active, not recruiting Nasopharyngeal Carcinoma Sun Yat-sen University February 4, 2017 Phase 2
NCT02779855 Not yet recruiting Breast Cancer|Ductal Carcinoma|Invasive Breast Carcinoma|Invasive Ductal Breast Carcinoma H. Lee Moffitt Cancer Center and Research Institute|Amgen April 30, 2017 Phase 1|Phase 2
NCT00001426 Completed Ovarian Neoplasm National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 3, 1995 Phase 2
NCT01419548 Withdrawn Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 29, 2011 Phase 1
NCT01051934 Completed Non-Small Cell Lung Cancer|Adenocarcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) December 29, 2009 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • Answer:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • Question 2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • Answer:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Paclitaxel | Paclitaxel supplier | purchase Paclitaxel | Paclitaxel cost | Paclitaxel manufacturer | order Paclitaxel | Paclitaxel distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID